PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment

Overview of attention for article published in The Journal of Allergy and Clinical Immunology, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog
twitter: 11 X users

facebook: 2 Facebook pages
podcasts: 1 podcast

Readers on

mendeley: 51 Mendeley

So far, Altmetric has seen 12 X posts from 11 X users, with an upper bound of 22,476 followers.

RT @jacionline: The development of therapies for asthma using conventional clinical trial design requires years. A new platform allows us t…

The development of therapies for asthma using conventional clinical trial design requires years. A new platform allows us to rapidly evaluate novel interventions, define and refine predictive biomarkers, and explore biomarkers of treatment response. htt…

RT @ATS_EOPH: PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Israel et al. J Allerg…

PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Israel et al. J Allergy Clin Immunol. 2021 Mar 2;S0091-6749(21)00352-3. https://t.co/4EqOGwFvPQ

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.